---
document_datetime: 2025-12-02 04:55:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/fruzaqla.html
document_name: fruzaqla.html
version: success
processing_time: 0.1011963
conversion_datetime: 2025-12-24 23:15:12.565028
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Fruzaqla

[RSS](/en/individual-human-medicine.xml/242276)

##### Authorised

This medicine is authorised for use in the European Union

fruquintinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Fruzaqla](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Fruzaqla is a cancer medicine used to treat adults with metastatic colorectal cancer (cancer of the large intestine and rectum that has spread to other parts of the body). It is used in people who have already received standard treatment and whose disease has got worse with treatment with trifluridine-tipiracil or regorafenib (other medicines to treat colorectal cancer) or who could not tolerate either of these medicines.

Fruzaqla contains the active substance fruquintinib.

Expand section

Collapse section

## How is Fruzaqla used?

Fruzaqla can only be obtained with a prescription and treatment should be started by a doctor experienced in giving cancer medicines.

The medicine is available as capsules to be taken by mouth. It is taken once a day for 21 days, followed by a 7-day rest period during which no medicine is taken. This 28-day treatment cycle should continue until the cancer gets worse. If the patient develops unacceptable side effects, the doctor may lower the dose or interrupt or stop treatment.

For more information about using Fruzaqla, see the package leaflet or contact your doctor or pharmacist.

## How does Fruzaqla work?

The active substance in Fruzaqla, fruquintinib, works by blocking the activity of proteins known as vascular endothelial growth factor (VEGF) receptors, which are found on the surface of cancer cells. These receptors are involved in the growth and spread of cancer cells and the development of blood vessels that supply the tumour. By blocking VEGF receptors, Fruzaqla helps to reduce the growth and spread of the cancer and cut off the blood supply that keeps cancer cells growing.

## What benefits of Fruzaqla have been shown in studies?

A main study involved 691 adults with metastatic colorectal cancer whose cancer was no longer responding to treatment with trifluridine-tipiracil or regorafenib or who could not tolerate either of these medicines. The results of the study showed that Fruzaqla was more effective than placebo (a dummy treatment) at increasing the time people lived. In this study, people treated with Fruzaqla lived for an average of 7.4 months compared with 4.8 months for those who received placebo.

The study also showed that people treated with Fruzaqla lived for an average of 3.7 months without their disease getting worse, compared with an average of 1.8 months for people who received placebo.

## What are the risks associated with Fruzaqla?

For the full list of side effects and restrictions with Fruzaqla, see the package leaflet.

The most common side effects with Fruzaqla (which may affect more than 1 in 10 people) include hypertension (high blood pressure), loss of appetite (anorexia), proteinuria (excess protein in the urine), palmar-plantar erythrodysaesthesia syndrome (rash and numbness on the palms and soles),  hypothyroidism (underactive thyroid gland), dysphonia (changes in the sound or tone of the voice), diarrhoea and weakness.

The most common serious side effects with Fruzaqla (which may affect up to 1 in 20 people) include gastrointestinal haemorrhage (bleeding in the stomach or intestines), pneumonia (lung infection), hypertension and gastrointestinal perforation (a hole in the wall of the stomach or intestines).

## Why is Fruzaqla authorised in the EU?

At the time of approval, there were very limited treatment options for people with metastatic colorectal cancer who no longer respond to treatment. The study showed that Fruzaqla increases the time these people live. The side effects with Fruzaqla are similar to those of other medicines that work in the same way and are considered acceptable.

The European Medicines Agency therefore decided that Fruzaqla's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Fruzaqla?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fruzaqla have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Fruzaqla are continuously monitored. Suspected side effects reported with Fruzaqla are carefully evaluated and any necessary action is taken to protect patients.

## Other information about Fruzaqla

Fruzaqla received a marketing authorisation valid throughout the EU on 20 June 2024.

Fruzaqla : EPAR - Medicine overview

Reference Number: EMA/216955/2024

English (EN) (132.57 KB - PDF)

**First published:** 10/07/2024

[View](/en/documents/overview/fruzaqla-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-165)

български (BG) (157.04 KB - PDF)

**First published:**

10/07/2024

[View](/bg/documents/overview/fruzaqla-epar-medicine-overview_bg.pdf)

español (ES) (130.93 KB - PDF)

**First published:**

10/07/2024

[View](/es/documents/overview/fruzaqla-epar-medicine-overview_es.pdf)

čeština (CS) (152.74 KB - PDF)

**First published:**

10/07/2024

[View](/cs/documents/overview/fruzaqla-epar-medicine-overview_cs.pdf)

dansk (DA) (131.21 KB - PDF)

**First published:**

10/07/2024

[View](/da/documents/overview/fruzaqla-epar-medicine-overview_da.pdf)

Deutsch (DE) (134.76 KB - PDF)

**First published:**

10/07/2024

[View](/de/documents/overview/fruzaqla-epar-medicine-overview_de.pdf)

eesti keel (ET) (129.43 KB - PDF)

**First published:**

10/07/2024

[View](/et/documents/overview/fruzaqla-epar-medicine-overview_et.pdf)

ελληνικά (EL) (154.53 KB - PDF)

**First published:**

10/07/2024

[View](/el/documents/overview/fruzaqla-epar-medicine-overview_el.pdf)

français (FR) (133.38 KB - PDF)

**First published:**

10/07/2024

[View](/fr/documents/overview/fruzaqla-epar-medicine-overview_fr.pdf)

hrvatski (HR) (152.57 KB - PDF)

**First published:**

10/07/2024

[View](/hr/documents/overview/fruzaqla-epar-medicine-overview_hr.pdf)

italiano (IT) (130.3 KB - PDF)

**First published:**

10/07/2024

[View](/it/documents/overview/fruzaqla-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (161.78 KB - PDF)

**First published:**

10/07/2024

[View](/lv/documents/overview/fruzaqla-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (152.35 KB - PDF)

**First published:**

10/07/2024

[View](/lt/documents/overview/fruzaqla-epar-medicine-overview_lt.pdf)

magyar (HU) (153.27 KB - PDF)

**First published:**

10/07/2024

[View](/hu/documents/overview/fruzaqla-epar-medicine-overview_hu.pdf)

Malti (MT) (155.13 KB - PDF)

**First published:**

10/07/2024

[View](/mt/documents/overview/fruzaqla-epar-medicine-overview_mt.pdf)

Nederlands (NL) (130.8 KB - PDF)

**First published:**

10/07/2024

[View](/nl/documents/overview/fruzaqla-epar-medicine-overview_nl.pdf)

polski (PL) (156.82 KB - PDF)

**First published:**

10/07/2024

[View](/pl/documents/overview/fruzaqla-epar-medicine-overview_pl.pdf)

português (PT) (132.88 KB - PDF)

**First published:**

10/07/2024

[View](/pt/documents/overview/fruzaqla-epar-medicine-overview_pt.pdf)

română (RO) (151.4 KB - PDF)

**First published:**

10/07/2024

[View](/ro/documents/overview/fruzaqla-epar-medicine-overview_ro.pdf)

slovenčina (SK) (152.66 KB - PDF)

**First published:**

10/07/2024

[View](/sk/documents/overview/fruzaqla-epar-medicine-overview_sk.pdf)

slovenščina (SL) (152.16 KB - PDF)

**First published:**

10/07/2024

[View](/sl/documents/overview/fruzaqla-epar-medicine-overview_sl.pdf)

Suomi (FI) (129.65 KB - PDF)

**First published:**

10/07/2024

[View](/fi/documents/overview/fruzaqla-epar-medicine-overview_fi.pdf)

svenska (SV) (130.69 KB - PDF)

**First published:**

10/07/2024

[View](/sv/documents/overview/fruzaqla-epar-medicine-overview_sv.pdf)

Fruzaqla : EPAR - Risk-management-plan

English (EN) (348.23 KB - PDF)

**First published:** 10/07/2024

[View](/en/documents/rmp-summary/fruzaqla-epar-risk-management-plan_en.pdf)

## Product information

Fruzaqla : EPAR - Product information

English (EN) (419.23 KB - PDF)

**First published:** 10/07/2024

**Last updated:** 27/11/2024

[View](/en/documents/product-information/fruzaqla-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-900)

български (BG) (522.35 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/bg/documents/product-information/fruzaqla-epar-product-information_bg.pdf)

español (ES) (390.51 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/es/documents/product-information/fruzaqla-epar-product-information_es.pdf)

čeština (CS) (552.64 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/cs/documents/product-information/fruzaqla-epar-product-information_cs.pdf)

dansk (DA) (419.78 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/da/documents/product-information/fruzaqla-epar-product-information_da.pdf)

Deutsch (DE) (368.97 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/de/documents/product-information/fruzaqla-epar-product-information_de.pdf)

eesti keel (ET) (356.26 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/et/documents/product-information/fruzaqla-epar-product-information_et.pdf)

ελληνικά (EL) (694.66 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/el/documents/product-information/fruzaqla-epar-product-information_el.pdf)

français (FR) (538.34 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/fr/documents/product-information/fruzaqla-epar-product-information_fr.pdf)

hrvatski (HR) (519.08 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/hr/documents/product-information/fruzaqla-epar-product-information_hr.pdf)

íslenska (IS) (365.77 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/is/documents/product-information/fruzaqla-epar-product-information_is.pdf)

italiano (IT) (448.95 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/it/documents/product-information/fruzaqla-epar-product-information_it.pdf)

latviešu valoda (LV) (514.06 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/lv/documents/product-information/fruzaqla-epar-product-information_lv.pdf)

lietuvių kalba (LT) (511.1 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/lt/documents/product-information/fruzaqla-epar-product-information_lt.pdf)

magyar (HU) (517.05 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/hu/documents/product-information/fruzaqla-epar-product-information_hu.pdf)

Malti (MT) (537.03 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/mt/documents/product-information/fruzaqla-epar-product-information_mt.pdf)

Nederlands (NL) (414.94 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/nl/documents/product-information/fruzaqla-epar-product-information_nl.pdf)

norsk (NO) (363.81 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/no/documents/product-information/fruzaqla-epar-product-information_no.pdf)

polski (PL) (550.58 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/pl/documents/product-information/fruzaqla-epar-product-information_pl.pdf)

português (PT) (363.25 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/pt/documents/product-information/fruzaqla-epar-product-information_pt.pdf)

română (RO) (502.65 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/ro/documents/product-information/fruzaqla-epar-product-information_ro.pdf)

slovenčina (SK) (565.01 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/sk/documents/product-information/fruzaqla-epar-product-information_sk.pdf)

slovenščina (SL) (505.91 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/sl/documents/product-information/fruzaqla-epar-product-information_sl.pdf)

Suomi (FI) (364.58 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/fi/documents/product-information/fruzaqla-epar-product-information_fi.pdf)

svenska (SV) (356.29 KB - PDF)

**First published:**

10/07/2024

**Last updated:**

27/11/2024

[View](/sv/documents/product-information/fruzaqla-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0004/G 26/11/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Fruzaqla : EPAR - All authorised presentations

English (EN) (50.92 KB - PDF)

**First published:** 10/07/2024

[View](/en/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-389)

български (BG) (79.5 KB - PDF)

**First published:**

10/07/2024

[View](/bg/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_bg.pdf)

español (ES) (49.87 KB - PDF)

**First published:**

10/07/2024

[View](/es/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_es.pdf)

čeština (CS) (93.4 KB - PDF)

**First published:**

10/07/2024

[View](/cs/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (51.21 KB - PDF)

**First published:**

10/07/2024

[View](/da/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (51.13 KB - PDF)

**First published:**

10/07/2024

[View](/de/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (50.93 KB - PDF)

**First published:**

10/07/2024

[View](/et/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (77.76 KB - PDF)

**First published:**

10/07/2024

[View](/el/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_el.pdf)

français (FR) (50.26 KB - PDF)

**First published:**

10/07/2024

[View](/fr/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (75.79 KB - PDF)

**First published:**

10/07/2024

[View](/hr/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (50.33 KB - PDF)

**First published:**

10/07/2024

[View](/is/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_is.pdf)

italiano (IT) (50.44 KB - PDF)

**First published:**

10/07/2024

[View](/it/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (94.15 KB - PDF)

**First published:**

10/07/2024

[View](/lv/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (82.04 KB - PDF)

**First published:**

10/07/2024

[View](/lt/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (79.63 KB - PDF)

**First published:**

10/07/2024

[View](/hu/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (80.89 KB - PDF)

**First published:**

10/07/2024

[View](/mt/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (50.72 KB - PDF)

**First published:**

10/07/2024

[View](/nl/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (51.38 KB - PDF)

**First published:**

10/07/2024

[View](/no/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_no.pdf)

polski (PL) (81.51 KB - PDF)

**First published:**

10/07/2024

[View](/pl/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_pl.pdf)

português (PT) (50.01 KB - PDF)

**First published:**

10/07/2024

[View](/pt/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_pt.pdf)

română (RO) (81.88 KB - PDF)

**First published:**

10/07/2024

[View](/ro/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (92.72 KB - PDF)

**First published:**

10/07/2024

[View](/sk/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (77.69 KB - PDF)

**First published:**

10/07/2024

[View](/sl/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (49.69 KB - PDF)

**First published:**

10/07/2024

[View](/fi/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (50.63 KB - PDF)

**First published:**

10/07/2024

[View](/sv/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Fruzaqla Active substance fruquintinib International non-proprietary name (INN) or common name fruquintinib Therapeutic area (MeSH) Colorectal Neoplasms Anatomical therapeutic chemical (ATC) code L01EK

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Fruzaqla as monotherapy is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan based chemotherapies, anti VEGF agents, and anti EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine tipiracil or regorafenib.

## Authorisation details

EMA product number EMEA/H/C/005979

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Takeda Pharmaceuticals International AG Ireland

Branch Block 2 Miesian Plaza 50 -58 Baggot Street Lower Dublin 2 D02 HW68 Ireland

Opinion adopted 25/04/2024 Marketing authorisation issued 20/06/2024 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Fruzaqla : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (104.02 KB - PDF)

**First published:** 19/07/2024

**Last updated:** 27/11/2024

[View](/en/documents/procedural-steps-after/fruzaqla-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Fruzaqla : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/462300/2023

English (EN) (6.31 MB - PDF)

**First published:** 10/07/2024

[View](/en/documents/assessment-report/fruzaqla-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Fruzaqla

Adopted

Reference Number: EMA/CHMP/168563/2024

English (EN) (105.01 KB - PDF)

**First published:** 26/04/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-fruzaqla_en.pdf)

#### News on Fruzaqla

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024) 26/04/2024

**This page was last updated on** 27/11/2024

## Share this page

[Back to top](#main-content)